Indium (111in) Chloride Curium Netherlands

Indium-111 chloride, the active ingredient in Indium (111in) Chloride Curium Netherlands, is a radiopharmaceutical presented as an injectable solution for intravenous use. It serves as a diagnostic tracer for imaging infection, inflammation, bone marrow activity and tumor staging in patients undergoing nuclear medicine examinations.

GNH USA supplies Indium (111in) Chloride Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Indium-111 chloride is employed in nuclear medicine to visualize sites of infection, inflammation, bone marrow activity and tumor involvement. - Infection and inflammation localization: enables precise detection of infectious foci and inflammatory lesions. - Bone marrow imaging: provides functional assessment of bone marrow distribution and activity. - Tumor imaging and staging: assists in identifying malignant lesions and evaluating disease extent.

Adverse reactions may occur following administration of Indium-111 chloride.

Common Side Effects: - Mild injection site pain or erythema. - Transient nausea or vomiting. - Flushing or warmth sensation. - Headache or dizziness. - Temporary hypotension. - Mild fatigue.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Significant hypotension requiring intervention. - Radiation‑induced tissue injury. - Hematologic abnormalities such as leukopenia. - Acute organ toxicity. - Severe skin reactions at the injection site.

Prior to use, clinicians should consider patient‑specific factors and safety measures. - Pregnancy: avoid use unless clearly needed, as fetal exposure is unknown. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal impairment: assess renal function, as excretion may be altered. - Hypersensitivity: screen for known allergies to indium compounds. - Radiation safety: implement appropriate protection for staff and other patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated before administration.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may interfere with imaging interpretation. - High‑dose iodine therapy: can alter biodistribution of indium‑111. - Myelosuppressive chemotherapy: may exacerbate hematologic effects.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of bleeding at injection site. - Immunosuppressants: may affect leukocyte labeling efficiency. - Beta‑blockers: could modify cardiovascular response to the tracer.